Geraud Valetin

Ms. Geraud Valetin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SNSharmeen Nishat
Sharmeen Nishat
MHMd Kamal Hossain
Md Kamal Hossain
GVGeraud Valetin
Geraud Valetin
FHFarzana Hossain
Farzana Hossain
SGShanika Gamage
Shanika Gamage
Peter AndreanaPeter Andreana
Peter Andreana
Background/Objectives: The MHCII-dependent, CD4+ T-cell zwitterionic polysaccharide PS A1 has been investigated as a promising carrier for vaccine development because it can induce an MHCII-dependent CD4+ response towards a variety of tumor-associated carbohydrate antigens (TACAs). However, PS A1 cannot elicit cytotoxic T lymphocytes through MHCI, which may or may not hamper its potential clinical use in cancer, infectious and viral vaccine development. This paper addresses PS A1 MHCI independence through the introduction of an MHCI epitope, the poliovirus (PV) peptide, to establish an MHCI- and MHCII-dependent vaccine. Methods: We synthesized a glycopeptide construct targeting the Thomsen-nouveau TACA (Tn-PV-PS A1) and a control Tn-PV peptide. C57BL/6 mice were immunized with both constructs, and the resulting T-cells were extracted from spleens. Results: Through cell proliferation assays, we show that Tn-PV-PS A1 elicits a robust CD4+ and CD8+ immune response. The resulting cytotoxic T lymphocytes are specific towards Tn-PV and trigger cell lysis of Tn-expressing EL4 cells. Conclusions: This study confirms PV-PS A1 as a robust MHCI- and MHCII-dependent carrier. This is the first report of MHCI dependence in a zwitterionic polysaccharide.

24 March 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
NRNadine Rosenglick
Nadine Rosenglick
GVGeraud Valetin
Geraud Valetin
KMKiran Marineni
Kiran Marineni
ENEuclydes P. Neto
Euclydes P. Neto
Peter AndreanaPeter Andreana
Peter Andreana
The surface of cancer cells is covered in abnormal carbohydrate antigens that facilitate tumor growth, immune evasion and metastasis. Overexpressed and often specific to cancer cells, these tumor-associated carbohydrate antigens (TACAs) offer a valuable handle for targeted immunotherapy and were soon targeted by TACA–protein conjugate vaccines. Despite good initial results, sTn-KLH conjugate Theratope® failed in clinical trials fifteen years ago for failure to improve life expectancy. This has been attributed to poor immunogenicity, inhomogeneous expression of TACAs within tumors, and vaccine carrier interference. This review covers the two decades of subsequent effort to overcome these limitations and the now large toolbox available to vaccine researchers to improve the outcome of anticancer vaccines: analogues and conformation-locked mimics of TACAs, monomolecular multivalent vaccines, more biologically relevant presentation of TACAs through clusters and glycopeptides, and a new generation of vaccine carriers to reduce carrier interference, immune reaction, or provide simple modular vaccine delivery platforms.

11 September 2025 in Molecules
Verified
Journal Article
Open access
PDF file
SGShanika M. P. Gamage
Shanika M. P. Gamage
GVGeraud Valetin
Geraud Valetin
SGSamir Ghosh
Samir Ghosh
PEPradheep Eradi
Pradheep Eradi
RBRahul S. Bagul
Rahul S. Bagul
Peter AndreanaPeter Andreana
Peter Andreana
Use of a microwave-labile leaving group, 2,4-dinitrophenyl (2,4-DNP), leads to O-glycosylation in 70–80% yields with high α-selectivity. The 2,4-DNP glycosyl donors, protected with electron-donating benzyl ethers, gave the best results under controlled microwave conditions, which were all conducted in polar aprotic solvents, such as DMF, and were all conducted in the absence of any reagent-activating additives such as a Lewis acid/base or Brønsted–Lowry acid/base. This method represents concerted efforts towards reagent-free neutral glycosylation.

2 April 2026 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
GVGeraud Valetin
Geraud Valetin
ASAndhina Satriani
Andhina Satriani
MLMatthew Lohman
Matthew Lohman
Peter AndreanaPeter Andreana
Peter Andreana
The triazole linker only plays a minor role in the immune response and allows for facile conjugation of amine- and azide-bearing antigens to vaccine carrier PS A1.